Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.
Sint Antonius Ziekenhuis, Nieuwegein, Netherlands
NorthShore University HealthSystem, Evanston, Illinois, United States
Mª Dolores Cárceles Barón, El Palmar, Murcia, Spain
Hospital do Rim e Hipertensão - Fundação Oswaldo Ramos, São Paulo, SP, Brazil
Hadassah Medical Organization, Jerusalem, Israel
Merck Sharp & Dohme GmbH, Haar, Germany
MSD Italia S.r.l., Rome, Italy
Assuta Medical Center, Tel Aviv, Israel
University of Patras, Department of Anesthesiology and Critical Care Medicine, Patras, Achaia, Greece
Hopital Foch, Suresnes, Ile de France, France
CHU Strasbourg Hôpital Civil, Strasbourg, Alsace, France
CHU Nancy, Vandoeuvre-Les-Nancy, Lorraine, France
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.